vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and STONERIDGE INC (SRI). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $205.2M, roughly 1.4× STONERIDGE INC). On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs -6.0%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs -7.4%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Stoneridge Inc is a global designer and manufacturer of advanced electrical and electronic components, integrated systems, and sensor solutions. It serves automotive, commercial vehicle, off-highway, and aerospace sectors, delivering products that boost vehicle safety, efficiency, connectivity, and environmental performance across key global markets.
ACAD vs SRI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $205.2M |
| Net Profit | $273.6M | — |
| Gross Margin | 90.8% | 16.2% |
| Operating Margin | 6.1% | -14.4% |
| Net Margin | 96.3% | — |
| Revenue YoY | 9.4% | -6.0% |
| Net Profit YoY | 90.3% | — |
| EPS (diluted) | $1.61 | $-2.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $205.2M | ||
| Q3 25 | $278.6M | $210.3M | ||
| Q2 25 | $264.6M | $228.0M | ||
| Q1 25 | $244.3M | $217.9M | ||
| Q4 24 | $259.6M | $218.2M | ||
| Q3 24 | $250.4M | $213.8M | ||
| Q2 24 | $242.0M | $237.1M | ||
| Q1 24 | $205.8M | $239.2M |
| Q4 25 | $273.6M | — | ||
| Q3 25 | $71.8M | $-9.4M | ||
| Q2 25 | $26.7M | $-9.4M | ||
| Q1 25 | $19.0M | $-7.2M | ||
| Q4 24 | $143.7M | — | ||
| Q3 24 | $32.8M | $-7.1M | ||
| Q2 24 | $33.4M | $2.8M | ||
| Q1 24 | $16.6M | $-6.1M |
| Q4 25 | 90.8% | 16.2% | ||
| Q3 25 | 92.2% | 20.3% | ||
| Q2 25 | 92.2% | 21.5% | ||
| Q1 25 | 91.7% | 21.2% | ||
| Q4 24 | 91.6% | 19.5% | ||
| Q3 24 | 92.5% | 20.8% | ||
| Q2 24 | 92.5% | 22.7% | ||
| Q1 24 | 88.8% | 20.2% |
| Q4 25 | 6.1% | -14.4% | ||
| Q3 25 | 12.8% | -1.6% | ||
| Q2 25 | 12.2% | -1.1% | ||
| Q1 25 | 7.9% | -1.5% | ||
| Q4 24 | 59.1% | -2.0% | ||
| Q3 24 | 12.6% | 0.1% | ||
| Q2 24 | 12.6% | 1.4% | ||
| Q1 24 | 7.4% | 0.1% |
| Q4 25 | 96.3% | — | ||
| Q3 25 | 25.8% | -4.5% | ||
| Q2 25 | 10.1% | -4.1% | ||
| Q1 25 | 7.8% | -3.3% | ||
| Q4 24 | 55.4% | — | ||
| Q3 24 | 13.1% | -3.3% | ||
| Q2 24 | 13.8% | 1.2% | ||
| Q1 24 | 8.0% | -2.6% |
| Q4 25 | $1.61 | $-2.76 | ||
| Q3 25 | $0.42 | $-0.34 | ||
| Q2 25 | $0.16 | $-0.34 | ||
| Q1 25 | $0.11 | $-0.26 | ||
| Q4 24 | $0.86 | $-0.22 | ||
| Q3 24 | $0.20 | $-0.26 | ||
| Q2 24 | $0.20 | $0.10 | ||
| Q1 24 | $0.10 | $-0.22 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $66.3M |
| Total DebtLower is stronger | — | $180.9M |
| Stockholders' EquityBook value | $1.2B | $179.8M |
| Total Assets | $1.6B | $551.2M |
| Debt / EquityLower = less leverage | — | 1.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $66.3M | ||
| Q3 25 | $258.0M | $54.0M | ||
| Q2 25 | $253.6M | $49.8M | ||
| Q1 25 | $217.7M | $79.1M | ||
| Q4 24 | $319.6M | $71.8M | ||
| Q3 24 | $155.1M | $54.1M | ||
| Q2 24 | $177.1M | $42.1M | ||
| Q1 24 | $204.7M | $48.4M |
| Q4 25 | — | $180.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $201.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.2B | $179.8M | ||
| Q3 25 | $917.3M | $251.2M | ||
| Q2 25 | $822.4M | $260.5M | ||
| Q1 25 | $765.2M | $253.1M | ||
| Q4 24 | $732.8M | $245.3M | ||
| Q3 24 | $577.2M | $271.4M | ||
| Q2 24 | $516.7M | $270.5M | ||
| Q1 24 | $464.0M | $277.3M |
| Q4 25 | $1.6B | $551.2M | ||
| Q3 25 | $1.3B | $632.1M | ||
| Q2 25 | $1.2B | $639.4M | ||
| Q1 25 | $1.1B | $657.4M | ||
| Q4 24 | $1.2B | $621.6M | ||
| Q3 24 | $976.9M | $662.5M | ||
| Q2 24 | $914.1M | $666.7M | ||
| Q1 24 | $855.1M | $675.4M |
| Q4 25 | — | 1.01× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.82× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $8.8M |
| Free Cash FlowOCF − Capex | — | $2.6M |
| FCF MarginFCF / Revenue | — | 1.3% |
| Capex IntensityCapex / Revenue | — | 3.0% |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $12.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $8.8M | ||
| Q3 25 | $74.3M | $3.6M | ||
| Q2 25 | $64.0M | $10.7M | ||
| Q1 25 | $20.3M | $10.9M | ||
| Q4 24 | $40.4M | $19.2M | ||
| Q3 24 | $63.2M | $10.8M | ||
| Q2 24 | $25.0M | $8.7M | ||
| Q1 24 | $29.1M | $9.1M |
| Q4 25 | — | $2.6M | ||
| Q3 25 | $73.9M | $-2.7M | ||
| Q2 25 | — | $7.4M | ||
| Q1 25 | — | $4.8M | ||
| Q4 24 | — | $14.0M | ||
| Q3 24 | $63.2M | $4.6M | ||
| Q2 24 | — | $1.5M | ||
| Q1 24 | — | $3.3M |
| Q4 25 | — | 1.3% | ||
| Q3 25 | 26.5% | -1.3% | ||
| Q2 25 | — | 3.3% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | 6.4% | ||
| Q3 24 | 25.2% | 2.2% | ||
| Q2 24 | — | 0.6% | ||
| Q1 24 | — | 1.4% |
| Q4 25 | — | 3.0% | ||
| Q3 25 | 0.1% | 3.0% | ||
| Q2 25 | — | 1.4% | ||
| Q1 25 | — | 2.8% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | 0.0% | 2.9% | ||
| Q2 24 | — | 3.0% | ||
| Q1 24 | — | 2.4% |
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 2.40× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 0.75× | 3.11× | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
SRI
| Control Devices | $51.7M | 25% |
| Electronics | $38.0M | 19% |
| EE | $34.2M | 17% |
| SE | $28.6M | 14% |
| NL | $24.5M | 12% |
| Stoneridge Brazil | $14.1M | 7% |
| Asia Pacific | $13.1M | 6% |
